PMID- 9754659
OWN - NLM
STAT- MEDLINE
DCOM- 19981009
LR  - 20190708
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 78
IP  - 2
DP  - 1998 Oct 5
TI  - Inhibition of cancer cell growth by all-trans retinoic acid and its analog 
      N-(4-hydroxyphenyl) retinamide: a possible mechanism of action via regulation of 
      retinoid receptors expression.
PG  - 248-54
AB  - In order to better understand the mechanisms that underlie the antiproliferative 
      effect of retinoids, we have examined the response of human carcinoma cell lines 
      to all-trans retinoic acid (RA) and N-(4-hydroxyphenyl) retinamide (4HPR) in 
      terms of cell growth, apoptosis and regulation of retinoic acid receptors (RARs) 
      and retinoid X receptors (RXRs) mRNA. GLC82 (lung adenocarcinoma), BGC823 
      (stomach adenocarcinoma) and EC109 (esophageal squamous carcinoma) cells were 
      treated with 10 microM of RA or 4HPR for various length of time and analyzed. The 
      results show that growth inhibition by RA and 4HPR in GLC82 and BGC823 cells 
      correlates with the induction of RARbeta2 gene, whereas RA resistance in EC109 
      cells parallels loss of RARbeta2 induction. Exogenous RARbeta2 expression did not 
      restore RA responsiveness in EC109 cells, but potentiated 4HPR-induced growth 
      inhibition, suggesting that 4HPR acts at least in part via the RARbeta receptor. 
      We speculate that the loss of RARbeta2 inducibility in EC109 cells may be due to 
      an unknown repressor.
FAU - Liu, G
AU  - Liu G
AD  - Laboratory of Molecular Oncology, Cancer Institute, CAMS and PUMC, Beijing, 
      China.
FAU - Wu, M
AU  - Wu M
FAU - Levi, G
AU  - Levi G
FAU - Ferrari, N
AU  - Ferrari N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Receptors, Retinoic Acid)
RN  - 0 (Retinoid X Receptors)
RN  - 0 (Transcription Factors)
RN  - 0 (retinoic acid receptor beta)
RN  - 187EJ7QEXL (Fenretinide)
RN  - 5688UTC01R (Tretinoin)
SB  - IM
MH  - Adenocarcinoma/drug therapy/pathology
MH  - Antineoplastic Agents/*pharmacology
MH  - Cell Division/drug effects
MH  - Drug Resistance, Neoplasm
MH  - Esophageal Neoplasms/drug therapy/pathology
MH  - Fenretinide/*pharmacology
MH  - Humans
MH  - Lung Neoplasms/drug therapy/pathology
MH  - Neoplasms/*drug therapy/*pathology/ultrastructure
MH  - Receptors, Retinoic Acid/*biosynthesis/genetics/physiology
MH  - Retinoid X Receptors
MH  - Stomach Neoplasms/drug therapy/pathology
MH  - Transcription Factors/biosynthesis/genetics/physiology
MH  - Transfection
MH  - Tretinoin/*pharmacology
MH  - Tumor Cells, Cultured
EDAT- 1998/10/01 02:02
MHDA- 2000/06/20 09:00
CRDT- 1998/10/01 02:02
PHST- 1998/10/01 02:02 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1998/10/01 02:02 [entrez]
AID - 10.1002/(SICI)1097-0215(19981005)78:2<248::AID-IJC20>3.0.CO;2-5 [pii]
AID - 10.1002/(sici)1097-0215(19981005)78:2<248::aid-ijc20>3.0.co;2-5 [doi]
PST - ppublish
SO  - Int J Cancer. 1998 Oct 5;78(2):248-54. doi: 
      10.1002/(sici)1097-0215(19981005)78:2<248::aid-ijc20>3.0.co;2-5.